financetom
Business
financetom
/
Business
/
Offshore vessel operator Tidewater reports Q3 net loss due to early debt extinguishment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Offshore vessel operator Tidewater reports Q3 net loss due to early debt extinguishment
Nov 10, 2025 1:52 PM

Overview

* Tidewater Q3 revenue rises 0.2% yr/yr to $341.1 mln, net loss reported

* Net loss impacted by $27.1 mln debt extinguishment loss

* Company updates 2025 revenue guidance to $1.33-$1.35 bln

Outlook

* Company updates 2025 revenue guidance to $1.33 to $1.35 bln

* Tidewater initiates 2026 revenue guidance of $1.32 to $1.37 bln

* Company sees 2026 gross margin between 48% and 50%

Result Drivers

* VESSEL UP-TIME - Improved vessel up-time exceeded initial estimates, contributing to revenue growth

* DAY RATE INCREASES - Meaningful day rate increases in certain segments offset softening in North Sea and West Africa

* FOREIGN EXCHANGE GAIN - $1.3 mln foreign exchange gain due to weakening U.S. dollar positively impacted net income and adjusted EBITDA

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $338.49

Vessel mln

Revenues

Q3 Net -$1.02

Income mln

Q3 $62.65

Operatin mln

g Income

Q3 $20.69

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the oil related services and equipment peer group is "buy"

* Wall Street's median 12-month price target for Tidewater Inc ( TDW ) is $68.00, about 22.2% above its November 7 closing price of $52.90

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Apple's Launch of iPhone SE4 Not Seen Impacting Revenue Guidance, UBS Says
Apple's Launch of iPhone SE4 Not Seen Impacting Revenue Guidance, UBS Says
Feb 18, 2025
10:22 AM EST, 02/18/2025 (MT Newswires) -- Apple ( AAPL ) 's launch of the fourth generation of the iPhone SE this week has most likely been taken into account in the company's revenue guidance for the March quarter, UBS said in a Sunday note. UBS analysts said that the average selling price of the iPhone could decline mid-single digits...
-- Definity Financial Brief: BMO Says Operating EPS estimates unchanged post a
-- Definity Financial Brief: BMO Says Operating EPS estimates unchanged post a "Modest" Q4 2024 operating EPS beat on better underwriting income
Feb 18, 2025
10:22 AM EST, 02/18/2025 (MT Newswires) -- Price: 60.29, Change: -1.37, Percent Change: -2.22 ...
Titanium Metal Company IperionX Secures New DoD Contract; Stock Jumps
Titanium Metal Company IperionX Secures New DoD Contract; Stock Jumps
Feb 18, 2025
Shares of titanium metal and critical materials company IperionX Limited ( IPX ) are trading higher on Tuesday. The company has been awarded a contract by the U.S. Department of Defense (DoD) valued at as much as $47.1 million, designed to improve the U.S. Defense Industrial Base by fostering the creation of a cost-effective and fully integrated domestic titanium supply...
Longeveron Cellular Therapy Granted International Non-Proprietary Name
Longeveron Cellular Therapy Granted International Non-Proprietary Name
Feb 18, 2025
10:23 AM EST, 02/18/2025 (MT Newswires) -- Longeveron ( LGVN ) said Tuesday that the World Health Organization approved laromestrocel for the non-proprietary name of the company's Lomecel-B cellular therapy. The US Food and Drug Administration granted Lomecel-B regenerative medicine advanced therapy designation and fast track designation to treat mild Alzheimer's disease, and orphan drug designation, fast track designation, and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved